Chemoprevention by perillyl alcohol coupled with viral gene therapy reduces pancreatic cancer pathogenesis

Molecular Cancer Therapeutics

Volumn 7, Issue 7, 2008, Pages 2042-2050

  Lebedeva, Irina V ^a   Su, Zhao Zhong ^b   Vozhilla, Nichollaq ^b   Chatman, Lejuan ^a   Sarkar, Devanand ^b,c   Dent, Paul ^b,c   Athar, Mohammad ^a   Fisher, Paul B ^b,c  

^a College of Physicians and Surgeons ^*  (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; INTERLEUKIN 24; PERILLYL ALCOHOL; INTERLEUKIN DERIVATIVE; INTERLEUKIN-24; TERPENE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER SURVIVAL; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG SAFETY; FETUS; GROWTH INHIBITION; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS PARTICLE; ANIMAL; APOPTOSIS; CELL PROLIFERATION; DISEASE MODEL; DRUG SCREENING; GENE THERAPY; GENETICS; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOVASCULARIZATION (PATHOLOGY); PANCREAS TUMOR; PATHOLOGY; SURVIVAL; TUMOR CELL LINE; VASCULARIZATION;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOPREVENTION; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; GENE THERAPY; HUMANS; INTERLEUKINS; MICE; MICE, NUDE; MONOTERPENES; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 51049104869     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0245     Document Type: Article

References (36)

1. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002;2:897-909.
2. Jaffee EM, Hruban RH, Canto M, Kern SE. Focus on pancreas cancer. Cancer Cell 2002;2:25-8.
3. Welsch T, Kleeff J, Friess H. Molecular pathogenesis of pancreatic cancer: advances and challenges. Curr Mol Med 2007;7:504-21.
4. Russo S, Butler J, Ove R, Blackstock AW. Locally advanced pancreatic cancer: a review. Semin Oncol 2007;34:327-34.
5. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 1995;11:2477-86.
6. Fisher PB. Is mda-7/IL-24 a "magic bullet" for cancer? Cancer Res 2005;65:10128-38.
7. Gupta P, Su ZZ, Lebedeva IV, et al. Mda-7/IL-24: Multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther 2006;111:596-628.
8. Lebedeva IV, Emdad L, Su ZZ, et al. Mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int J Oncol 2007;31:985-1007.
9. Lebedeva IV, Sauane M, Gopalkrishnan RV, et al. Mda-7/IL-24: exploiting cancer's Achilles' heel. Mol Ther 2005;11:4-18.
10. Sarkar D, Su ZZ, Lebedeva IV, et al. mda-7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc Natl Acad Sci U S A 2002;99:10054-9.
11. Sauane M, Gopalkrishnan RV, Sarkar D, et al. MDA-7/IL-24: novel cancer growth suppressing and apoptosis inducing cytokine. Cytokine Growth Factor Rev 2003;14:35-51.
12. Cunningham CC, Chada S, Merritt JA, et al. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther 2005;11:149-59.
13. Fisher PB, Gopalkrishnan RV, Chada S, et al. mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: fromthe laboratory into the clinic. Cancer Biol Ther 2003;2:S23-37.
14. Fisher PB, Sarkar D, Lebedeva IV, et al. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol 2007;224:300-7.
15. Tong AW, Nemunaitis J, Su D, et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther 2005;11:160-72.
16. Lebedeva IV, Sarkar D, Su ZZ, et al. Molecular target-based therapy of pancreatic cancer. Cancer Res 2006;66:2403-13.
17. Lebedeva IV, Su ZZ, Sarkar D, et al. Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis. Oncogene 2005;24:585-96.
18. Su Z, Lebedeva IV, Gopalkrishnan RV, et al. A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc Natl Acad Sci U S A 2001;98:10332-7.
19. Belanger JT. Perillyl alcohol: applications in oncology. Altern Med Rev 1998;3:448-57.
20. Berchtold CM, Chen KS, Miyamoto S, Gould MN. Perillyl alcohol inhibits a calcium-dependent constitutive nuclear factor-κB pathway. Cancer Res 2005;65:8558-66.
21. Bishop WR, Kirschmeier P, Baum C. Farnesyl transferase inhibitors: mechanism of action, translational studies and clinical evaluation. Cancer Biol Ther 2003;2:S96-104.
22. Crowell PL, Chang RR, Ren ZB, Elson CE, Gould MN. Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem 1991;266:17679-85.
23. da Fonseca CO, Landeiro JA, Clark SS, Quirico-Santos T, da Costa Carvalho Mda G, Gattass CR. Recent advances in the molecular genetics of malignant gliomas disclose targets for antitumor agent perillyl alcohol. S1:2-1:8 Surg Neurol 2006;65 Suppl 1:S1:2-1:8; discussion S1:8-1:9.
24. Crowell PL. Prevention and therapy of cancer by dietary monoterpenes. J Nutr 1999;129:775-8S.
25. Gould MN. Cancer chemoprevention and therapy by monoterpenes. Environ Health Perspect 1997;105 Suppl 4:977-9.
26. Azzoli CG, Miller VA, Ng KK, et al. A phase I trial of perillyl alcohol in patients with advanced solid tumors. Cancer Chemother Pharmacol 2003;51:493-8.
27. Bae VL, Jackson-Cook CK, Brothman AR, Maygarden SJ, Ware JL. Tumorigenicity of SV40 T antigen immortalized human prostate epithelial cells: association with decreased epidermal growth factor receptor (EGFR) expression. Int J Cancer 1994;58:721-9.
28. Su ZZ, Lebedeva IV, Sarkar D, et al. Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner. Oncogene 2003;22:1164-80.
29. Su ZZ, Madireddi MT, Lin JJ, et al. The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc Natl Acad Sci U S A 1998;95:14400-5.
30. Schwarz RE, McCarty TM, Peralta EA, Diamond DJ, Ellenhorn JD. An orthotopic in vivo model of human pancreatic cancer. Surgery 1999;126:562-7.
31. Burke YD, Stark MJ, Roach SL, Sen SE, Crowell PL. Inhibition of pancreatic cancer growth by the dietary isoprenoids farnesol and geraniol. Lipids 1997;32:151-6.
32. Stark MJ, Burke YD, McKinzie JH, Ayoubi AS, Crowell PL. Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol. Cancer Lett 1995;96:15-21.
33. Liston BW, Nines R, Carlton PS, et al. Perillyl alcohol as a chemopreventive agent in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. Cancer Res 2003;63:2399-403.
34. Lantry LE, Zhang Z, Crist KA, et al. Chemopreventive efficacy of promising farnesyltransferase inhibitors. Exp Lung Res 2000;26:773-90.
35. Lebedeva IV, Su ZZ, Vozhilla N, et al. Mechanismof in vitro pancreatic cancer cell growth inhibition by mda-7/IL-24 and perillyl alcohol. Cancer Res. In press 2008.
36. Bardeesy N, Aguirre AJ, Chu GC, et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A 2006;103:5947-52.